Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Nevro reports revenue decline in Q3 but advances AI therapy

Nevro faced revenue decline in Q3 2024 but maintained stability and improved cash position.
Strategic actions to enhance commercial execution and product innovation show promise for future growth.
Challenges in revenue and profitability persist, but opportunities in therapy expansion and market diversification exist.
Continued focus on cost management and strategic exploration to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Thursday, June 8, 2023 at 10:30 am Eastern Time REDWOOD CITY, Calif. , May 22, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal, Nevro's CEO and President, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 10:30 am Eastern Time at the Marriott Marquis Hotel in New York, NY.

Nevro to Present at Jefferies Healthcare Conference

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts could bring significant FCF growth and stock price appreciation.

Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued

REDWOOD CITY, Calif. , April 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced on April 24, 2023, the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock (the RSU Award) and performance unit awards covering 135,623 shares of its common stock (the PSU Award and together, the Awards) to Kevin Thornal, who joined Nevro as its Chief Executive Officer & President, in connection with his commencement of employment.

Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript.

Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript

REDWOOD CITY, Calif. , April 26, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2023 financial results.

Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Nevro (NVRO)? Wall Street Analysts Think 53.7%

First Randomized Controlled Trial Specifically Powered to Assess Restoration of Neurological Function in Patients with Intractable Painful Diabetic Neuropathy Breakthrough Device Designation Provides Expedited Review for Marketing Application to Expand Nevro's FDA Labeling REDWOOD CITY, Calif. , April 24, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has enrolled the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, which is the first prospective randomized controlled trial (RCT) to assess restoration of neurological function as a primary objective in patients with intractable PDN.

Nevro Announces Enrollment of First Patient in PDN Sensory Study

Today Nevro announced the appointment of a new CEO/president along with its preliminary 2023 Q1 financial results. With a possible recession looming, investors are exiting the cash-flow-negative medtech today.

Why Nevro Stock Is Tanking Today

D. Keith Grossman to be Appointed as Executive Chairman Company Announces Preliminary, Unaudited Worldwide Revenue for First Quarter of 2023 of $96.3 Million and Reaffirms Full-Year 2023 Revenue and Non-GAAP Adjusted EBITDA Guidance REDWOOD CITY, Calif. , April 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal has been appointed Chief Executive Officer and President of Nevro, effective April 24, 2023, and will also be appointed to the Board of Directors.

Nevro Names Kevin Thornal as New Chief Executive Officer and President

Company to Host Conference Call on Wednesday, April 26, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , March 29, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2023 after the market closes on April 26, 2023.

Nevro to Report First Quarter 2023 Financial Results

Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif. , March 7, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has now initiated the U.S. full market launch of its HFX iQ spinal cord stimulation (SCS) system, following the completion of a successful limited market release.

Nevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain

Friday, March 24, 2023 at 2:00 pm Eastern Time REDWOOD CITY, Calif. , Feb. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D.

Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.

Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat

Nevro Corporation (NYSE:NVRO ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, CEO and President Rod MacLeod - Chief Financial Officer Conference Call Participants Joanne Wuensch - Citibank Chris Pasquale - Nephron Vik Chopra - Wells Fargo Brandon Vazquez - William Blair Robbie Marcus - J.P. Morgan Dave Rescott - Truist Securities Simran Kaur - Piper Sandler Operator Good afternoon.

Nevro Corporation (NVRO) Q4 2022 Earnings Call Transcript

REDWOOD CITY, Calif. , Feb. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its fourth quarter and full-year 2022 financial results.

Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance

Nevro Corp. has seen multiple boom-bust cycles in its share price, and we are in the bust phase again. Unlike previous times, the Nevro Corp. growth story has been impaired, with revenues stable for a while now.

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?

Wednesday, March 1, 2023 at 8:45 am Eastern Time REDWOOD CITY, Calif. , Feb. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related  Practices and Policies REDWOOD CITY, Calif. , Jan. 31, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2023 Bloomberg Gender-Equality Index (GEI) for the second consecutive year.

Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year

Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full year ended December 31, 2022 after the market closes on February 16, 2023.

Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results

REDWOOD CITY, Calif. , Jan. 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain.

Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook

Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of the Board Company to Present Today at J.P.

Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance

Monday, January 9, 2023 at 3:45 pm Pacific Time / 6:45 pm Eastern Time REDWOOD CITY, Calif. , Dec. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

News for Nevro Stock (NVRO)